Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Advanced Dementia
NEJM 372:2533-2540, Mitchell, S.L., 2015
Memantine for Dementia in Adults Older than 40 years with Downs Syndrome (MEADOWS): a Randomised,double-blind,placebo-controlled Trial
Lancet 379:528-536, Hanney,M.,et al, 2012
Long-Term Effects of the Concomitant Use of Memantine with Cholinesterase Inhibition in Alzheimer Disease
JNNP 80:600-607, Lopez,O.L.,et al, 2009
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
Phase 2 Safety Trial Targeting Amyloid � Production With a ?-Secretase Inhibitor in Alzheimer Disease
Arch Neurol 65:1031-1038, Fleisher,A.S.,et al., 2008
A 24-Week Open-Label Extension Study of Memantine in Moderate to Severe Alzheimer Disease
Arch Neurol 63:49-54, Reisberg,B.,et al, 2006
Effect of Enhanced Psychosocial Care on Antipsychotic Use in Nursing Home Residents with Severe Dementia; Cluster Randomised Trial
BMJ 332:756-758,741, Fossey,J.,et al, 2006
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease
NEJM 355:1525-1538,1604, Schneider,L.S.,et al, 2006
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil, A Randomized Controlled Trial
JAMA 291:317-324, Tariot,P.N.,et al, 2004
Alzheimer's Disease
NEJM 351:56-67, Cummings,J.L, 2004
Atypical Antipsychotic Drugs in the Treatment of Behavioural and Psychological Symptoms of Dementia: Systematic Review
BMJ 329:75-78, Lee,P.E.,et al, 2004
Memantine in Moderate-to-Severe Alzheimer's Disease
NEJM 348:1333-1341, Reisberg,B.,et al, 2003
Tolerability of Memantine in Combination with Cholinesterase Inhibitors in Dementia Therapy
Int Clin Psychopharm 18:81-85, Hartmann,S.& Mobius, H.J., 2003
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Galantamine (Reminyl) for Alzheimer's Disease
Medical Letter 43:53-54, , 2001
A 24-Week, Randomized, Double-Blind Study of Donepezil in Moderate to Severe Alzheimer's Disease
Neurol 57:613-620, Feldman,H.,et al, 2001
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
NEJM 345:1515-1521,1567, in 'T Veld,B.A.,et al, 2001
Donepezil Therapy in Clinical Practice, A Randomized Crossover Study
Arch Neurol 57:94-99, Greenberg,S.M.,et al, 2000
Rivastigmine (Exelon) for Alzheimer's Disease
The Medical Letter 42:93-94, , 2000
A 5-Month, Randomized, Placebo-controlled Trial of Galantamine in AD
Neurol 54:2269-2276, Tariot,P.N.,et al, 2000
Galantamine in AD
Neurol 54:2261-2268, Raskind,M.A.,et al, 2000
Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled
BMJ 318:633-640, 615, Rosler,M.,et al, 1999
A Randomized Trial of Risperidone,Placebo,and Haloperidol for Behavioral Symptoms of Dementia
Neurol 53:946-955,899, DeDeyn,P.P.,et al, 1999
Clinical Benefits of Donepezil:Results from a Long-Term Phase III Extension Trial
Neurol 52:A174, Doody,R.S.,et al, 1999
Treatment of Alzheimer's Disease
NEJM 341:1670-1679, Mayeux,R.&Sano,M, 1999
A 24-Week, Double-Blind, Placebo-Controlled Trial of Donepezil in Pts with Alzheimer's Disease
Neurol 50:136-145, Rogers,S.,et al, 1998
Pharmacologic Treatment of Cognition in Alzheimer's Dementia
Neurol 51:S36-S44, Farlow,M.R.&Evans,R.M., 1998
Donepezil Improves Cognition & Global Function in Alzheimer Dis, 15-Week Doub-Blind, Plac-Contr Study
Arch Int Med 158:1021-1031, 9411998., Rogers,S.L.,et al, 1998
Nonsteroidal Anti-Inflammatory Drug use and Alzheimer-Type Pathology in Aging
Neurol 50:986-990, Mackenzie,I.&Munoz,D.G., 1998
Ginkgo Biloba for Dementia
The Medical Letter 40:63-64, , 1998
Metrifonate Benefits Cognitive, Behvioral, and Global Function in Patients with Alzheimer's Disease
Neurol 50:1222-1230, 12031998., Morris,J.C.,et al, 1998
Metrifonate Treatment of the Cognitive Deficits of Alzheimer's Disease
Neurol 50:1214-1221, 12031998., Cummings,J.L.,et al, 1998
Risk of Alzheimer's Disease and Duration of NSAID Use
Neurol 48:626-632, Stewart,W.F.,et al, 1997
Donepezil (Aricept) for Alzheimer's Disease
The Medical Letter 39:53-54, , 1997
Clinical Features and Pharmacologic Treatment of Behavioral Symptoms of Alzheimer's Disease
Neurol 48 (Suppl 6) :S17-S24997., Borson,S.&Raskind,M.A., 1997
Clinical Experience with Donepezil Hydrochloride:A Case Study Perspective
Advan Therapy 14:305-311, Geldmacher,D.S., 1997
Tacrine
Lancet 345:625-630, Davis,K.L.&Powchik,P., 1995
Management of the Behavioral Manifestations of Dementia
Arch Int Med 155:250-260, Yeager,B.F.,et al, 1995
Effectiveness & Safety of Velnacrine for Treatment of Alzheimer's Disease:A Double Blind, Placebo-Controlled Study
Arch Int Med 155:1766-1772, Antuono,P.G.,et al, 1995
Do Nonsteroidal Anti-Inflammatory Drugs Decrease Risk for Alzheimer's Disease, Rotterdam Study
Neurol 45:1441-1445, Andersen,K.,et al, 1995
Hepatotoxic Effects of Tacrine Administration in Patients with Alzheimer's Disease
JAMA 271:992-998, Watkins,P.B.,et al, 1994
30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients with Alzheimer's Disease
JAMA 271:985-991, 10231994., Knapp,M.J.,et al, 1994